About Exela Pharma
Exela Pharma is a Healthcare company based in Lenoir (United States) founded in 2005 by Phanesh Koneru. Sterile injectable pharmaceuticals are manufactured alongside CDMO services. Exela Pharma has raised $7.09 million across 5 funding rounds from investors including Premier. The company has 247 employees. Its chief executive, as recorded, is Phanesh Koneru. Exela Pharma offers products and services including Sterile Injectables and CDMO Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is EXELA PHARMA SCIENCES LLC.
Company details
Exela Pharma was founded in 2005 and is headquartered in Lenoir, United States, within the pharmaceutical sector. Proprietary and generic sterile injectables are developed and produced, covering the full lifecycle from research and development through manufacturing and distribution. Contract development and manufacturing services are offered for liquid vials, IV bags, lyophilized vials, and pre-filled syringes. Regulatory support is also provided to clients.
- Headquarters Lenoir, United States
- Employees 247
- Founders Phanesh Koneru
- SectorsHealthcare
- Website exelapharma.com
- Social LinkedIn
- Legal Name Exela Pharma Sciences Llc
- Total Equity Funding$7.09M (USD)
in 5 rounds
- Investors
- Employee Count247
Products & Services of Exela Pharma
Exela Pharma offers a comprehensive portfolio of products and services, including Sterile Injectables and CDMO Services.
Develops and manufactures sterile injectables to address healthcare needs.
Provides R&D, manufacturing, and logistics for pharmaceutical clients.
Funding Insights of Exela Pharma
Exela Pharma has successfully raised a total of $7.09M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.09M
- Total Rounds 5
- First Round $6.25M
(Jun 2008)
- Investors Count 1
All 5 funding rounds of Exela Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | Series B | – | – | ||
| Aug 2015 | $419,828 | Private Equity Round | – | – | – |
| Aug 2015 | $419,828 | Series A | – | – | – |
| Jul 2013 | $1M | Debt – Conventional | – | – | – |
| Jun 2008 | $6.25M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Exela Pharma
Exela Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Premier.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cloud-based practice management software is provided for organizations. | 1968 | premierinc.com | Charlotte, United States |
Investor details for Exela Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exela Pharma
30 people are tracked at Exela Pharma (9 in leadership, 21 in team); the tracked headcount is 247.
| Name | Role | Group |
|---|---|---|
Phanesh Koneru | Co-Founder & CEO | Leadership |
Mark Hartman | Chief Commercial Officer | Leadership |
Murthy Mallipeddi | Founder, Chief Scientific Officer | Leadership |
Patrick Welsh | Vice President of Sales | Leadership |
Don Overton | Vice President of Finance | Leadership |
Gregory Cutler | Director Of Special Projects (DEA Compliance / Corporate Security) | Leadership |
Kelly Abernethy | Director Of Execution | Leadership |
Mo Ahmed | Senior Director of Research Development | Leadership |
Celeste C. Brantolino | Senior Director Of Learning And Development (head Of Department) | Leadership |
Niasia Mcintyre | Project Manager | Team |
Yeng Vang | Senior Technology Transfer Specialist | Team |
Bethany S. Lingle | Project Manager II - Execution Team | Team |
Omotunde Okubanjo | Clinical Research Scientist | Team |
Justin Haney | Operations Manager | Team |
Brian Thompson | Manager, API Synthesis | Team |
Leonardo Zea | Technology Transfer Specialist | Team |
Samuel Miller | Research Scientist I - API Synthesis | Team |
Thomas Siegel | Process Engineer | Team |
Mary Summerlin | Project Accountant | Team |
Mark Landschoot | Manager of Operations Accounting and Analysis | Team |
10 more people are available in the full profile.
Complete people profiles for Exela Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Exela Pharma
3 dated milestones of Exela Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Exela Pharma is founded.
- Funding First funding round of $6.2M.
- Funding Latest funding round, Series B,.
Web traffic of Exela Pharma
The website of Exela Pharma (exelapharma.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▼ 86.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Exela Pharma (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exela Pharma
Complete news archive for Exela Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exela Pharma
Exela Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Exela Pharma is headquartered in Lenoir, United States. It is registered at Lenoir, North Carolina, United States.
Phanesh Koneru is the CEO of Exela Pharma, as recorded in our data. They have also founded this company.
Exela Pharma is a funded company, having raised a total of $7.09M across 5 funding rounds to date. The company's 1st funding round was a Series A of $6.25M, raised on Jun 2008.
Exela Pharma has 247 employees.
Exela Pharma was founded in 2005 and is headquartered in Lenoir, United States, within the pharmaceutical sector. Proprietary and generic sterile injectables are developed and produced, covering the full lifecycle from research and development through manufacturing and distribution. Contract development and manufacturing services are offered for liquid vials, IV bags, lyophilized vials, and pre-filled syringes. Regulatory support is also provided to clients.
Exela Pharma offers Sterile Injectables and CDMO Services.
Exela Pharma has 1 investor. Key investors include Premier.
Exela Pharma operates through Exela Pharma Sciences Llc.